0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Vitamin D Therapy and Cardiac Function in Chronic Kidney Disease—Reply

Stefan D. Anker, MD, PhD; Stephan von Haehling, MD, PhD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4178.
Text Size: A A A
Published online

Extract

In Reply: We agree with Dr Slatopolsky that many aspects merit attention in the discussion of paricalcitol. We also agree that paricalcitol is effective and even faster than 1,25-hydroxyvitamin D3 in the suppression of elevated levels of parathyroid hormone.1 This is also the case in patients with significantly elevated levels of phosphorus, a subgroup of patients usually deemed resistant to 1,25-hydroxyvitamin D3.2 However, in the space of an editorial, we were not able to provide a complete overview of paricalcitol and therefore primarily focused on summarizing the evidence in the field of CKD and left ventricular hypertrophy, which was the area of concern for the PRIMO trial. No beneficial effects of paricalcitol have yet been demonstrated in this regard.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

June 6, 2012
Costas Fourtounas, MD, PhD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4168.
June 6, 2012
Sanjay Rajagopalan, MD; Christopher T. Chan, MD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4170.
June 6, 2012
Ravi Thadhani, MD, MPH; Hector Tamez, MD, MPH; Scott D. Solomon, MD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4176.
June 6, 2012
Eduardo Slatopolsky, MD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4172.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();